Replies to post #314740 on Avid Bioservices Inc (CDMO)

[biopharm]

1 Peregrine Pharmaceuticals
2 Epiontis GmbH, Berlin, Germany
3 Precision Medicine, Frederick MD

I imagine Precision Medicine had a good look under the biomarker hood of PS Targeting and they must have liked what they had seen....so the question is why would Bird / Bird have given the green light for Precision for Medicine to buy out Epiontis at this critical point in time....hmmmm

If one reads what is going on here below and look into the timeline that just a short couple weeks later Precision for Medicine buys out Epiontis ....it is clearly because of PS Targeting reasons....but Precision Medicine Group is the parent company and not public but could go IPO with a PS Targeting cornerstone molecule and just thinking out loud....but something is being stirred and my concern is some trying to play spoiler for some Peregrine deal that keeps R&D going strong, because it is all about BIOMARKERS and paradigm shifts ...

I always like to say The Enlightenment Age of Disease....is here

Comprehensive Service Offering--Precision Value & Health
NEW ALIGNMENT OF INDUSTRY-LEADING SERVICES PROVIDES INTEGRATED SCIENCE, RESEARCH, TECHNOLOGY, ANALYTICS, AND COMMUNICATIONS TO INNOVATORS IN LIFE SCIENCES

NEWS PROVIDED BY
Precision Medicine Group

Sep 21, 2017, 09:21 ET

BETHESDA, Md., Sept. 21, 2017 /PRNewswire/ -- Precision Medicine Group, a specialized services company supporting next generation approaches to drug development and commercialization, today announced the formation of Precision Value & Health—a focused set of complementary services working in concert to help pharmaceutical and life sciences clients establish the clinical, economic, and humanistic value of innovative therapies to payers, healthcare professionals, and patients.

In today's rapidly evolving healthcare landscape, the demonstration of value has never been more important to ensure patient access to life-changing therapies. Through health research and analysis, value message development, and brand engagement, Precision Value & Health harnesses and deploys the insights of leading market access thought leaders, former payer executives, academics, policy makers, and strategic marketers.

Representing a unique solution for navigating the entire route to commercialization, Precision Value & Health comprises Precision's industry-leading business units: Precision for Value, Precision Health Economics, and precisioneffect.

Precision for Value develops distinctive payer value propositions and solutions that differentiate medical innovations and ensure optimal market access and reimbursement by leveraging insights from an experienced and highly regarded team of payer executives.
Precision Health Economics provides innovative health policy research and economic analysis for influencing policy debates on critical healthcare issues, along with state-of-the-art evidence synthesis methods, models, strategies, and communications plans.
precisioneffect is an award-winning healthcare advertising agency dedicated to working with companies seeking to change the standard of care by identifying and upending status quo behaviors among physicians, patients, and caregivers.
With more than 500 employees in 10 offices across North America and Europe, Precision Value & Health offers clients a proven and unprecedented opportunity to establish clinical, economic, and humanistic value across the commercialization continuum.

"Precision Value & Health has a wide range of experts and services that help our customers stay ahead in an ever-changing healthcare landscape," said Dan Renick, president of Precision Value & Health. "Unlike other enterprises that take cookie-cutter approaches, our expertise is in recognizing change and delivering new customized solutions for a dynamic environment. Our experienced management team is excited to lead this comprehensive level of expertise and deliver it seamlessly to the marketplace."